Targeted functional imaging in breast cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 3, 2007, Pages 346-353

  Kumar, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA IODOVINYL 11BETA METHOXYESTRADIOL I 123; 4,16ALPHA DIFLUORO 11BETA METHOXYESTRADIOL F 18; 5 FLUORO 2,3 BIS(4 HYDROXYPHENYL)PENTANENITRILE F 18; ANTIESTROGEN; ESTRADIOL TC 99M; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; RADIOLIGAND; TAMOXIFEN; TRACER; UNCLASSIFIED DRUG;

BINDING ASSAY; BREAST CANCER; CANCER SCINTISCANNING; EDITORIAL; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMAGE ENHANCEMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33847111148     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0284-2     Document Type: Editorial

References (93)

1. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003;39:1718-29.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. De Waard F. Epidemiology of breast cancer; a review. Eur J Cancer Clin Oncol 1983;19:1671-6.
4. Van-Bon Martens MJH, Verbeek ALM, Peeters PHM, Luning P, Were JM. Een Overzicht van de epidemiology van, borstkanker in Nederland. Ned Tijdschr Geneeskd 1990;134:287-91.
5. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long term tissue culture. Cancer Res 1976;36:4595-601.
6. Soule HD, McGrath CM. Estrogen responsive proliferation of clonal human breast carcinoma in athymic mice. Cancer Res Lett 1980;10:177-89.
7. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in atomic mice. Cancer Res 1985;45:584-90.
8. Colton T, Greenberg ER, Noller K, Resseguie L, Van Bennekom C, Heeren T, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA 1993;269:2096-100.
9. Miller WR. Estrogens and the risk of breast cancer. In: Miller WR, editor. Estrogen and breast cancer. Berlin Heidelberg New York: Springer; 1996; pp 35-62.
10. Van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 1985;45:2900-4.
11. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase 17-beta hydroxy-steroid dehydrogenase and intratissular sex hormone concentration in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25.
12. Vermeulen A. Human mammary cancer as a site of sex steroid metabolism. Cancer Surv 1986;5:585-95.
13. Feher T, Bodrogi L, Vallent K, Ribai Z. Role of human adipose tissue in the production and metabolism of steroid hormones. Endocrinologie 1982;80:173-80.
14. Paridaens RJ. Characterisation and therapeutic use of hormone dependency of breast cancer. Acta Clin Belg 1988;43:127-38.
15. Wyld DK, Chester JD, Perren TJ. Endocrine aspects of the clinical management of breast cancer - current issues. Endocrine-Related Cancer 1998;5:97-110.
16. Locker CY. Hormonal therapy of breast cancer. Cancer Treat Rev 1998;24:221-40.
17. Buzdar AU. Tamoxifen's clinical applications: old and new. Arch Family Med 2000;9:906-12.
18. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001;28:291-304.
19. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, et al. Comparision of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 1997;57:3723-7.
20. Stoll BA. Rechallenging breast cancer with tamoxifen therapy. Clin Oncol 1983;9:347-51.
21. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumours from breast cancer patients. J Clin Oncol 1992;10:304-10.
22. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, et al. Predictors of response to second line endocrine therapy for breast cancer. Breast Cancer Res Treat 1997;45:219-24.
23. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev 1990;11:221-65.
24. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
25. Wolf DM, Jordan VC, William L. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat 1993;27:27-40.
26. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-33.
27. Hulka BS. Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res 1996;395:289-95.
28. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumours. Cancer Res 1992;52:483-6.
29. Johnston SR. Systemic treatment of metastatic breast cancer. Hosp Med 2001;62:289-95.
30. Vogel CL. Update on the current use of hormonals as therapy in advanced breast cancer. Anticancer Drugs 2003;14:265-73.
31. Kuiper GG, Enmark E, Pelti-Huikko M, Nilson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30.
32. Hall JM, McDonnel DP. The estrogen receptor beta-isoform of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and anti estrogens. Endocrinology 1999;140:5566-78.
33. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiological Rev 2001;81:1535-65.
34. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferate preinvasive mammary tumours. Cancer Res 2001;61:2537-41.
35. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, et al. Estrogen receptor beta in breast cancer. Endocr-Related Cancer 2002;9:1-13.
36. Donegan WL. Prognostic factors; stage and receptor status in breast cancer. Cancer 1992;70:1755-64.
37. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, et al. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 1980;16:323-31.
38. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984;53 3 suppl:630-43.
39. Merkel DE, Osborne CK. Use of steroid receptor assays in cancer management. Rev Endocrinol Rel Cancer 1988;30:5-12.
40. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer. New York: Raven Press; 1975; pp 1-7.
41. McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977;39 6 suppl:2934-47.
42. Van Netten JP, Armstrong JB, Carlyle SS, Goodchild NL, Thornton IG, Brigden ML, et al. Estrogen receptor distribution in the peripheral, intermediate, and central regions of breast cancers. Eur J Cancer Clin Oncol 1998;24:1885-9.
43. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-85.
44. Castagnetta L, Traina A, Di Carlo A, Latteri AM, Carruba G, Leake RE. Heterogeneity of soluble and nuclear estrogen receptor status of involved nodes in relation to primary breast cancer. Eur J cancer Clin Oncol 1987;23:31-5.
45. Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hanna WH. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol 1987;23:819-26.
46. Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 2004;45:1-7.
47. Zeicher M, Delcorde A, Quivy J, Dupuis Y, Vervist A, Fruhling J. Radioimaging of human breast carcinoma engrafts in mice by [I-123]-labelled Z-17alpha-iodovinyl-11beta-chloromethyl-estradiol. Nucl Med Biol 1996;23:69-73.
48. Bindal RD, Carlson KE, Reiner GCA, Katzenellenbogen JA. 11beta-Chloromethyl-[H-3] estradiol-17beta: a very high affinity, reversible ligand for estrogen receptor. J Steroid Biochem 1987;28:361-70.
49. Quivy J, Henrot P, Wauters M, Bastin B, Wilmotte JM, Deblaton M. Improvement of the tissular distribution of Z-CMIV, a high specific estrogen estrogen receptor seeking steroid by means of molecular encapsulation. In: Gotog S, editor. Advances in steroidal analyses. Budapest: Akademiai Kiado; 1993; pp 77-82.
50. Katzenellenbogen JA, Carlson KE, Heiman DF, Goswami R. Receptor binding radio pharmaceuticals for imaging breast tumours: estrogen receptor interactions and selectivity of tissue uptake of halogenated estrogen analogs. J Nucl Med 1980;21:550-8.
51. Katzenellenbogen JA, Hsiung HM, Carlson KE, Mcguire WC, Kraay RJ, Katzenellenbogen BS. Iodohexestrols II. Characterisation of the binding and estrogenic activity of iodinated hexestrol derivatives in vitro and in vivo. Biochemistry 1975;14:1742-50.
52. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labelled estrogens and their selective uptakes in target tissues in immature rats. J Nucl Med 1984;25:1212-21.
53. Landvatter SW, Katzenellenbogen JA, McElvany KD, Welch MJ. (2R*,3S*)-1-[I-125] iodo-2,3-bis(4-hydroxyphenyl) pentane([I-125]iodonorhexesterol) and (2R*,3S*)-1-[Br- 77]bromo-2,3-bis(4-hydroxyphenyl) pentane ([Br-77]bromonorhexesterol), two gamma emitting estrogens that show receptor mediated uptake by target tissues in vivo. J Med Chem 1982;25:1307-12.
54. Hochberg RB. Iodine-125-labelled estradiol: a gamma emitting analog of estradiol that binds to the estrogen receptor. Science 1979;205:1138-40.
55. Hochberg RB, Rosner W. Interaction of 16 alpha-[I 125]-iodoestradiol with estrogen receptor and other steroid binding proteins. Proc Natl Acad Sci USA 1980;77:328-32.
56. Lippman ME, Do HMT, Hochberg RB. Specific estrogen receptor binding and biological effects of 16 alpha-iodoestradiol on human breast cancer cells. Cancer Res 1981;41:3150-4.
57. McElvany KD, Carlson KE, Welch MJ, Senderoff SG, Katzenellenbogen JA, Los Alamos Medical Radioisotope Group. In vivo comparison of 16 alpha-[Br-77]bromoestradiol-17beta and 16alpha-[I-125]Iodoestradiol-17beta. J Nucl Med 1982;23:420-4.
58. Hanson RN, Franke LA. Preparation and evaluation of 17 alpha-[I-125]-iodovinyl-11beta-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication. J Nucl Med 1984;25:998-1002.
59. Hanson RN, Seitz DE, Botarro JC. E-17 alpha-[I-125] iodovinylestradiol: an estrogen receptor seeking radio pharmaceutical. J Nucl Med 1982;23:431-6.
60. Jagoda EM, Gibson RE, Goodgold H, Ferreira N, Francis BE, Reba RC, et al. [I-125] 17 alpha iodovinyl 11 beta methoxyestradiol: in vivo and in vitro properties of a high affinity estrogen receptor radio pharmaceutical. J Nucl Med 1984;25:472-7.
61. Nakatsuka I, Ferreira NL, Eckelman WC, Francis BE, Rzeszotarski WJ, Gibson RE, et al. Synthesis and evaluation of (17alpha,20E)-21-[I-125] iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-diol and (17alpha,20E)-21-[I-125] iodo-11beta-methoxy-19-norpregna-1,3,5 (10), 20 tetraene-3,17 diol (17 alpha-(iodovinyl)estradiol derivatives) as high specific activity potential radio pharmaceuticals. J Med Chem 1984;27:1287-91.
62. 99mTc-GAP-EDL. Eur J Nucl Med Mol imaging 2006 Sep 2; [Epub ahead of print]. DOI 10.1007/s00259-006-0191-6.
63. French AN, Napolitano E, Van Brocklin HF, Hanson RN, Welch MJ, Katzenellenbogen JA. Synthesis, radiolabelling and tissue distribution of 11beta-fluoroalkyl- and 11beta fluoroalkoxy-substituted estrogens: target tissue uptake selectivity and defluorination of a homologous series of fluorine-18-labelled estrogens. Nucl Med Biol 1993;20:31-47.
64. Pomper MG, Van Brocklin H, Thieme AM, Thomas RD, Kiesewetter DO, Carlson KE, et al. 11Beta-methoxy-,11beta ethyl-and 17alpha-ethynyl-substituted 16 alpha fluoroestradiols: receptor based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 1990;33:3143-55.
65. Van Brocklin HF, Carlson KE, Katzenellenbogen JA, Welch MJ. 16 Beta-([F-18] fluoro) estrogens: systematic investigation of a new series of fluorine-18-labelled estrogens as potantial imaging agents for estrogen receptor positive breast tumours. J Med Chem 1993;36:1619-29.
66. Van Brocklin HF, Rocque PA, Lee HV, Carlson KE, Katzenellenbogen JA, Welsch MJ16Beta-[F-18]fluoromoxesterol: a potent , metabolically stable positron emission topography imaging agent for estrogen receptor positive human breast tumours. Life Sci 1993;53:811-9.
67. Yang DJ, Li C, Kuang LR, Price JE, Buzdar AU, Tansey W, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 1994;55:53-67.
68. 18F] fluoro-17beta-estradiol. J Med Chem 2005;48:6366-78.
69. Katzenellenbogen JA, Senderoff SG, McElvany KD, O'Brien HA, Welch MJ. 16alpha-[Br-77]Bromoestradiol-17beta: a high specific activity, gamma emitting tracer with uptake in rat uterus and induced mammary tumours. J Nucl Med 1981;22:42-7.
70. McElvany KD, Katzenellenbogen JA, Shafer KE, Siegel BA, Senderoff SG, Welch MJ. 16alpha-[Br-77]Bromoestradiol-17beta: dosimetry and preliminary clinical studies. J Nucl Med 1982;23:425-30.
71. Preston DF, Spicer JA, Baranvzuk C, Fabian KG, Baxter NL, Martin R, et al. Clinical results of breast cancer detection by imageable estradiol (I-123 E2). Eur J Nucl Med 1990;17: A159,430.
72. Schober O, Schicha H, Reiners C, Biersack HJ, Moser E. Breast cancer imaging with radioiodinated oestradiol. Lancet 1990;335:1522.
73. 123I-labeled estradiol in breast cancer-receptor scintigraphy. Nuklearmedizin 1991;30:84-99.
74. Kenady DE, Pavlik EJ, Nelson K, van Nagell JR, Gallion H, DePriest PD, et al. Images of estrogen receptor positive breast tumours produced by estradiol labelled with iodine I-123 at 16 alpha. Arch Surg 1993;128:1373-81.
75. Kiesewetter DO, Katzenellenbogen JA, Kilbourn MR, Welch MJ. Synthesis of 16-fluoroestrogens by unusually facile fluoride ion displacement reactions: prospects for the preparation of fluoride-18 labelled estrogens. J Org Chem 1984;49:4900-5.
76. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74.
77. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-8.
78. McGuire AH, Dehdashti F, Seigel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of alpha-[F-18]fluoro 17beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31.
79. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Clinical correlation of FDG and FES PET imaging with estrogen receptors in breast cancers and response to systemic therapy. Clin Cancer Res 1996;2:933-9.
80. Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G, et al. F-18-labelled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor binding radiopharmaceuticals. Steroids 2002;67:765-75.
81. Seimbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G, et al. Impact on estrogen receptor binding and target tissue uptake of [F-18]fluorine substitution at the 16alpha-position of fluvestrant (Falsodex; ICI 182,780). Nucl Med Biol 2004;31: 691-8.
82. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24:2793-9.
83. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001;19:3808-16.
84. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone reeptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
85. Ariazi EA, Clark GM, Mertz JE. Estrogen related receptor gamma associate with unfavourable and favourable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8.
86. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s.
87. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response tometastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6.
88. Hanson RE, Seitz DE, Botarro JC. E-17alpha-[I-123]iodovinylestradiol : an estrogen receptor seeking radiopharmaceutical. J Nucl Med 1982;23:431-6.
89. Ribeiro-Barras MJ, Foulon C, Baulieu JL, Guilloteau D, Bougnoux P, Lansac J, et al. Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)-Part II. Preliminary results in patients with breast carcinoma. Nucl Med Biol 1992;19:263-7.
90. Rijks LJ, Boer GJ, Endert E, de Bruin K, Janssen AG, van Royen EA. The Z isomer of 11 beta-methoxy-17alpha-[I-123] iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer. Nucl Med Biol 1997;24:65-75.
91. Nachar O, Rousseau JA, Lefebvre B, Ouellet R, Hasrat A, vanLier JE. Biodistribution, dosimetry and metabolism of 11beta-methoxy-(17alpha,20 E/Z)-[I-123]iodovinylestradiol in healthy women and breast cancer patients. J Nucl Med 1999; 40:1728-36.
92. Bennink RJ, Rijks LJ, Tienhoven GV, Noorduyn LA, Janssen AG, Sloof GW. Estrogen receptor status in primary breast cancer: iodine 123-labelled cis -11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology 2001;220:774-9.
93. 99mTc-depreotide scintigraphy. J Nucl Med 2006;47:6-13.